TCGA-AO-A12F-01A-11R-A115-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.470
- G2M_CHECKPOINT+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- ANGIOGENESIS+0.280
- MTORC1_SIGNALING+0.220
- OXIDATIVE_PHOSPHORYLATION+0.220
- NOTCH_SIGNALING+0.200
- SPERMATOGENESIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.470
- ESTROGEN_RESPONSE_EARLY-0.390
- PROTEIN_SECRETION-0.330
- ALLOGRAFT_REJECTION-0.310
- ESTROGEN_RESPONSE_LATE-0.290
- ANDROGEN_RESPONSE-0.260
- INFLAMMATORY_RESPONSE-0.220
- P53_PATHWAY-0.220
- BILE_ACID_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0RU-01A-11R-A084-07 | — | E | 0.842 |
| 2 | TCGA-OR-A5KY-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.826 |
| 3 | AUR-AG0M-TTM1-A-2-1-R-A743-41 | — | A | 0.823 |
| 4 | TCGA-BA-A8YP-01A-11R-A39I-07 | — | — | 0.815 |
| 5 | MNG541 | — | — | 0.814 |
| 6 | TCGA-FJ-A871-01A-11R-A352-07 | — | — | 0.809 |
| 7 | TCGA-A2-A04U-01A-11R-A115-07 | — | E | 0.809 |
| 8 | TCGA-B6-A0I6-01A-11R-A034-07 | — | E | 0.806 |
| 9 | SRR1516100 | — | — | 0.799 |
| 10 | TCGA-A2-A0T0-01A-22R-A084-07 | — | E | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |